4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

3 - NKGen Biotech, Inc. (0001845459) (Issuer)

4 - NKGen Biotech, Inc. (0001845459) (Issuer)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

NT 10-Q - NKGen Biotech, Inc. (0001845459) (Filer)

SCHEDULE 13D - NKGen Biotech, Inc. (0001845459) (Subject)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

NT 10-K - NKGen Biotech, Inc. (0001845459) (Filer)

8-K - NKGen Biotech, Inc. (0001845459) (Filer)

424B3 - NKGen Biotech, Inc. (0001845459) (Filer)

SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer's disease ("AD"). An activated clinical site refers to a site that has completed all necessary preparations, such as staff training and protocol set up, enabling the site to begin recruiting and enrollin

New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that its Chairman & Chief Executive Officer, Paul Y. Song, M.D., has invested $2.65 million cash, derived from the recent successful sale of another biotech busin

SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company's Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer's disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13–17, 2025. Presentation Details Title: Us

SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025. BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique op

Moderate Alzheimer's disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17 doses improved from moderate to mild AD within just 3 months. One patient stabilized at their improved score, while the other patient continued to show ongoing improvement. Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-controlled Phase 2a part of the study. SANTA ANA, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on

SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ("AD/PD™ 2025") taking place online and in Vienna, Austria from April 1 – 5, 2025. AD/PD™ 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer

SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit (the "Summit") to be held in Boston, MA, from March 18–20, 2025. Dr. Song's presentation will highlight troculeucel, the Company's autologous, non-genetically modified NK cell therapy, as a potential treatment for neurodegenerative diseases. The

Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol "NKGN" for common stock and "NKGNW" for warrants.NKGen Biotech, Inc. ("NKGen" or the "Company") has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange ("SEC") reporting requirements.The Company has cancelled its previously announced 1-for-6 reverse stock split. Enrollment in randomized Phase 2a Alzheimer's trial is expected to be completed by the end of Q2 with an initial readout planned for later in 2025. SANTA ANA, Calif., March 04,

SANTA ANA, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the administration of troculeucel, an expanded autologous NK cell therapy, in a stroke patient under a single compassionate use, Investigational New Drug ("IND") cleared by the U.S. Food and Drug Administration ("FDA"). Stroke is the second leading cause of death and long-term disability. It is accompanied by an increase in chronic neuroinflammation that can contribute to further subsequent ne

SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the administration of troculeucel, an expanded autologous NK cell therapy, in an FTD patient under a single compassionate use, Investigational New Drug ("IND") cleared by the U.S. Food and Drug Administration ("FDA"). It is estimated that about 60,000 people in the U.S. are currently living with FTD. Up to 40% of FTD cases have a genetic component and the patient receiving troculeucel is kn